drugset / Trial / NCT01606163
Safety and Pharmacokinetics Study of Healthy Male Adults When Repeatedly Administered Through Intravenous Injection
RandomizedParallel-groupDouble-blindPrevention
Summary
The purpose of this study is to evaluate the safety and pharmacokinetics of healthy male adults when subjects are repeatedly administered GC1102 (Hepabig\_Gene) through intravenous injection.
Timeline
- Start
- 2012-08
- Primary completion
- 2013-06
- Completion
- 2013-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | LENVERVIMAB | Monoclonal antibody | 3 ml | Intravenous |
| Subject | LENVERVIMAB | Monoclonal antibody | 5 ml | Intravenous |
| Subject | LENVERVIMAB | Monoclonal antibody | 8 ml | Intravenous |
| Subject | LENVERVIMAB | Monoclonal antibody | 30000 iu | Intravenous |
| Subject | LENVERVIMAB | Monoclonal antibody | 50000 iu | Intravenous |
| Subject | LENVERVIMAB | Monoclonal antibody | 80000 iu | Intravenous |